Eriox 20mg / 1.5ml. 80mg / 6ml Infusion. Solution
PDF Leaflet Revision Date: 12 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including breast, lung, ovarian, and prostate cancer.
Dosage (summary)
75-100 mg/mu00b2 IV infusion every 3 weeks, depending on cancer type.
Special Populations
- Hepatic impairment
- Elderly
- Children
Pregnancy & Breastfeeding
Contraindicated; teratogenic in animals.
Key Drug Interactions
- Cytochrome P450-3A inhibitors/inducers
- Dexamethasone
- Cisplatin
Contraindications
- Severe hypersensitivity to docetaxel or polysorbate 80
- Neutrophil count <1500 cells/mmu00b3
- Severe liver impairment
Common side effects
- Neutropenia
- Hypersensitivity reactions
- Fluid retention
- Nausea
- Alopecia
Counselling Points
- Monitor for signs of infection
- Report any severe allergic reactions
- Use effective contraception during treatment
Serious warnings
- Increased treatment-related mortality in liver impairment
- Severe hypersensitivity reactions
- Fluid retention requiring monitoring
Important Disclaimer
The Eriox 20mg / 1.5ml. 80mg / 6ml Infusion. Solution professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
